Engineered T-Cells take on tough blood cancers in first human trial

NCT ID NCT06834282

Recruiting now Disease control Sponsor: CERo Therapeutics Holdings, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new treatment called CER-1236 for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis) that have not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to check safety and see if the therapy can shrink or eliminate the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA AML REFRACTORY ACUTE MYELOID LEUKEMIA

Contacts and locations

Show contact details

Locations

Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States

Contact Email: •••••@•••••
Sarah Cannon Research Insitute
RECRUITING

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of California, Davis Comprehensive Cancer Center
NOT_YET_RECRUITING

Sacramento, California, 95817, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.